GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alliance Pharma PLC (LSE:APH) » Definitions » Net Income

Alliance Pharma (LSE:APH) Net Income : £-7.1 Mil (TTM As of Jun. 2023)


View and export this data going back to 2001. Start your Free Trial

What is Alliance Pharma Net Income?

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax. Alliance Pharma's Net Income for the six months ended in Jun. 2023 was £5.1 Mil. Its Net Income for the trailing twelve months (TTM) ended in Jun. 2023 was £-7.1 Mil.

Net Income is linked to the most popular Earnings per Share (Diluted) number. Alliance Pharma's Earnings per Share (Diluted) for the six months ended in Jun. 2023 was £0.01.


Alliance Pharma Net Income Historical Data

The historical data trend for Alliance Pharma's Net Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alliance Pharma Net Income Chart

Alliance Pharma Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Net Income
Get a 7-Day Free Trial Premium Member Only Premium Member Only 18.36 25.01 8.03 7.32 0.94

Alliance Pharma Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Net Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.24 -0.92 13.10 -12.17 5.11

Alliance Pharma Net Income Calculation

Net Income is the net profit that a company earns after deducting all costs and losses including cost of goods, SGA, DDA, interest expenses, non-recurring items and tax.

Net Income
= Revenue - Cost of Goods Sold - Selling, General, & Admin. Expense - Research & Development - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= EBITDA - Depreciation, Depletion and Amortization - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Operating Income - Interest Expense - Non Operating Income (NRI) - Tax Expense + Others
= Pre-Tax Income - Tax Expense + Others

Alliance Pharma's Net Income for the fiscal year that ended in Dec. 2022 is calculated as

Net Income(A: Dec. 2022 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=5.208+-4.272+0+1.1102230246252E-16
=0.9

Alliance Pharma's Net Income for the quarter that ended in Jun. 2023 is calculated as

Net Income(Q: Jun. 2023 )
= Pre-Tax Income + Tax Provision + Net Income (Discontinued Operations) + Others
=6.236+-1.127+0+0
=5.1

Net Income for the trailing twelve months (TTM) ended in Jun. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-7.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Alliance Pharma  (LSE:APH) Net Income Explanation

Net Income is the most widely cited number in reporting a company's profitability. It is linked to the most popular earnings-per-share (EPS) number through:

Alliance Pharma's Earnings per Share (Diluted) (EPS) for the quarter that ended in Jun. 2023 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.

EPS is most useful for companies that have:

A predictable business
Consistent accounting methods
And few restructurings

The dividend paid to preferred stocks needs to be subtracted from the total net income in the calculation of EPS because common stock holders are not entitled to that part of the net income.


Be Aware

Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred Net Income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.

Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.

If net earnings is less than 10%, likely to be in a highly competitive business.


Alliance Pharma Net Income Related Terms

Thank you for viewing the detailed overview of Alliance Pharma's Net Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Alliance Pharma (LSE:APH) Business Description

Traded in Other Exchanges
Address
Bath Road, Avonbridge House, Chippenham, Wiltshire, GBR, SN15 2BB
Alliance Pharma PLC is a player in the healthcare market. The company's business includes the acquisition, marketing, and distribution of consumer healthcare and pharmaceutical products. The group operates in two segments: Consumer Healthcare brands and Prescription Medicines. It generates the majority of its revenue from the Consumer Healthcare segment. Its products include Aloclair, Biodermatin, Changmin, Decapional, Effadiane, and Fazol. The company generates maximum revenue from the Kelo-cote brand. Geographically, it derives a majority of its revenue from Europe, the Middle East, and Africa (EMEA).

Alliance Pharma (LSE:APH) Headlines

From GuruFocus

Q4 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2021 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q3 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2020 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q2 2019 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024

Q4 2022 Amphenol Corp Earnings Call Transcript

By GuruFocus Research 01-22-2024